Reconsidering the role of blood-brain barrier in Alzheimer's disease: From delivery to target

被引:22
|
作者
Sousa, Joao Andre [1 ]
Bernardes, Catarina [1 ]
Bernardo-Castro, Sara [1 ,2 ]
Lino, Miguel [3 ]
Albino, Ines [3 ]
Ferreira, Lino [2 ,3 ]
Bras, Jose [4 ]
Guerreiro, Rita [4 ]
Tabuas-Pereira, Miguel [1 ,2 ]
Baldeiras, Ines [2 ,5 ]
Santana, Isabel [1 ,2 ,5 ]
Sargento-Freitas, Joao [1 ,2 ,3 ,5 ]
机构
[1] Ctr Hosp & Univ Coimbra, Dept Neurol, Coimbra, Portugal
[2] Univ Coimbra, Fac Med, Coimbra, Portugal
[3] Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal
[4] Van Andel Inst, Dept Neurodegenerat Sci, Grand Rapids, MI USA
[5] Univ Coimbra, Ctr Innovat Biomed & Biotechnol CIBB, Coimbra, Portugal
来源
FRONTIERS IN AGING NEUROSCIENCE | 2023年 / 15卷
关键词
blood-brain barrier; nanomaterials; Alzheimer's disease; neurodegenerative diseases; amyloid clearance; genetic targeting; AMYLOID-BETA; MOUSE MODEL; NEUROVASCULAR DYSFUNCTION; DRUG-DELIVERY; THERAPEUTIC STRATEGIES; COGNITIVE IMPAIRMENT; P-GLYCOPROTEIN; CLEARANCE; RAGE; FLOW;
D O I
10.3389/fnagi.2023.1102809
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The existence of a selective blood-brain barrier (BBB) and neurovascular coupling are two unique central nervous system vasculature features that result in an intimate relationship between neurons, glia, and blood vessels. This leads to a significant pathophysiological overlap between neurodegenerative and cerebrovascular diseases. Alzheimer's disease (AD) is the most prevalent neurodegenerative disease whose pathogenesis is still to be unveiled but has mostly been explored under the light of the amyloid-cascade hypothesis. Either as a trigger, bystander, or consequence of neurodegeneration, vascular dysfunction is an early component of the pathological conundrum of AD. The anatomical and functional substrate of this neurovascular degeneration is the BBB, a dynamic and semi-permeable interface between blood and the central nervous system that has consistently been shown to be defective. Several molecular and genetic changes have been demonstrated to mediate vascular dysfunction and BBB disruption in AD. The isoform epsilon 4 of Apolipoprotein E is at the same time the strongest genetic risk factor for AD and a known promoter of BBB dysfunction. Low-density lipoprotein receptor-related protein 1 (LRP-1), P-glycoprotein, and receptor for advanced glycation end products (RAGE) are examples of BBB transporters implicated in its pathogenesis due to their role in the trafficking of amyloid-beta. This disease is currently devoid of strategies that change the natural course of this burdening illness. This unsuccess may partly be explained by our misunderstanding of the disease pathogenesis and our inability to develop drugs that are effectively delivered to the brain. BBB may represent a therapeutic opportunity as a target itself or as a therapeutic vehicle. In this review, we aim to explore the role of BBB in the pathogenesis of AD including the genetic background and detail how it can be targeted in future therapeutic research.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Alzheimer's disease and drug delivery across the blood-brain barrier: approaches and challenges
    Iqbal, Iram
    Saqib, Fatima
    Mubarak, Zobia
    Latif, Muhammad Farhaj
    Wahid, Muqeet
    Nasir, Bushra
    Shahzad, Hamna
    Sharifi-Rad, Javad
    Mubarak, Mohammad S.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2024, 29 (01) : 313
  • [22] Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease
    Roney, C
    Kulkarni, P
    Arora, V
    Antich, P
    Bonte, F
    Wu, AM
    Mallikarjuana, NN
    Manohar, S
    Liang, HF
    Kulkarni, AR
    Sung, HW
    Sairam, M
    Aminabhavi, TM
    JOURNAL OF CONTROLLED RELEASE, 2005, 108 (2-3) : 193 - 214
  • [23] Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease
    Erickson, Michelle A.
    Banks, William A.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2013, 33 (10) : 1500 - 1513
  • [24] Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease
    Bell, Robert D.
    Zlokovic, Berislav V.
    ACTA NEUROPATHOLOGICA, 2009, 118 (01) : 103 - 113
  • [25] The Case for Blood-Brain Barrier Dysfunction in the Pathogenesis of Alzheimer's Disease
    Jeynes, Brian
    Provias, John
    JOURNAL OF NEUROSCIENCE RESEARCH, 2011, 89 (01) : 22 - 28
  • [26] Role of ischmic blood-brain barrier on amyloid plaques development in Alzheimer's disease brain
    Pluta, Ryszard
    CURRENT NEUROVASCULAR RESEARCH, 2007, 4 (02) : 121 - 129
  • [27] Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease
    Yamazaki, Yu
    Kanekiyo, Takahisa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (09)
  • [28] The Role of Clusterin Transporter in the Pathogenesis of Alzheimer's Disease at the Blood-Brain Barrier Interface: A Systematic Review
    Fareed, Muhammad Mazhar
    Qasmi, Maryam
    Aziz, Shaan
    Voelker, Elisabeth
    Foerster, Carola Yvette
    Shityakov, Sergey
    BIOMOLECULES, 2022, 12 (10)
  • [29] Research Progress on Natural Plant Molecules in Regulating the Blood-Brain Barrier in Alzheimer's Disease
    Wu, Weidong
    Huang, Jiahao
    Han, Pengfei
    Zhang, Jian
    Wang, Yuxin
    Jin, Fangfang
    Zhou, Yanyan
    MOLECULES, 2023, 28 (22):
  • [30] Interactions between glial cells and the blood-brain barrier and their role in Alzheimer's disease
    Zhao, Ming
    Jiang, Xue-Fan
    Zhang, Hui-Qin
    Sun, Jia-Hui
    Pei, Hui
    Ma, Li-Na
    Cao, Yu
    Li, Hao
    AGEING RESEARCH REVIEWS, 2021, 72